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Abstract
Background: The use of intravenous (IV) or topical tranexamic acid (TXA) in total hip arthroplasty has been proven
to be effective and safe in total hip arthroplasty. However, which of these two administration routes is better has
not been determined. The combined administration of TXA has been used in total knee arthroplasty with
satisfactory results. We hypothesized that combined application of TXA may be the most effective way without
increased rate of thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolisms (PE) in patients
subjected to primary total hip replacement (THA). A meta-analysis was conducted to compare the efficacy and
safety of the combined use of tranexamic acid (TXA) relative to topical or intravenous (IV) use alone for treatment
of primary THA. The outcomes included total blood loss, postoperative hemoglobin decline, transfusion rates, and
the incidence rates of deep vein thrombosis (DVT) and pulmonary embolisms (PE).
Methods: We searched electronic databases including PubMed, EMBASE, the Cochrane Library, Web of Science,
the Chinese Biomedical Literature database, the CNKI database, and Wanfang Data until September 2016.
The references of the included articles were also checked for additional potentially relevant studies. There were
no language restrictions for the search. The data of the included studies were analyzed using RevMan 5.3 software.
Results: Seven studies met the inclusion criteria, encompassing a total of 1762 patients. Our meta-analysis
demonstrated that total blood loss, postoperative hemoglobin decline, and transfusion rates were significantly
lower for patients that received the combined treatment compared to patients that received either topical or
intravenous administration of TXA. No statistical differences were found in the incidence of deep venous
thrombosis (DVT) or pulmonary embolism (PE).
Conclusion: The group that received the combined treatment had lower total blood loss, postoperative
hemoglobin decline, and transfusion rates without an increased rate of thrombotic events (DVT or PE). The topical
or intravenous use of TXA in primary THA is generally considered to be safe and effective. This meta-analysis
demonstrated that combined TXA application may be superior to topical or intravenous application of TXA alone.
However, larger, high-quality randomized control trials are required for greater confidence in this finding.
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Background
Total hip arthroplasty (THA) is an effective surgical
procedure for patients with end-stage hip diseases, but is
always accompanied by substantial blood loss and high
transfusion rates [1, 2]. Although allogenic blood trans-
fusion may be beneficial to patients, it may induce con-
siderable side effects, such as delay of hip functional
recovery, adverse reaction to the transfusion, cardiovas-
cular dysfunction, disease transmission, and joint infec-
tion [3–6]. Additionally, allogeneic blood transfusions
are costly procedures [7]. Lately, the use of TXA has
been expanded for use in THA procedures [8].
Tranexamic acid (TXA) is a synthetic amino acid
analogue that acts as a competitive inhibitor of plas-
minogen and finally interferes with fibrinolysis [9]. TXA
can decrease blood loss and reduce transfusion require-
ments, and has been successfully used in some surgical
procedures including THA [8, 10–12]. Intravenous or
topical TXA administration for total hip arthroplasty has
been demonstrated to be effective and safe in total hip
arthroplasty [8, 13–16]. However, which of these two
administration routes may be more effective remains
controversial due to different merits and drawbacks. The
combined administration of TXA has been used in
total knee arthroplasty with showed satisfactory re-
sults [17–19]. Therefore, we proposed a hypothesis that
the combined application of TXA in THA may be the
most effective administration strategy without increased
rate of thrombotic events.
The efficacy and safety of combined application versus
topical or intravenous application of tranexamic acid in
THA remains controversial. To our knowledge, no
meta-analysis had been previously reported. Therefore,
we conducted this meta-analysis to compare these treat-
ment strategies, evaluating outcomes of total blood loss,
postoperative hemoglobin decline, transfusion rates, the
incidence rate of deep vein thrombosis (DVT), and the
incidence rate of pulmonary embolisms (PE).
Methods
Search strategy
We searched the electronic databases including PubMed,
EMBASE, the Cochrane Library, Web of Science, the
Chinese Biomedical Literature database, the CNKI database,
and Wanfang Data until September 2016. The references of
the included literatures were also checked for potentially
relevant studies. There were no language restrictions. The
data of the included studies were analyzed using RevMan
5.3 software. The key words used in search methods includ-
ing “tranexamic acid”, “total hip arthroplasty”. We made a
joint retrieval of free and subject words. The Boolean opera-
tors were used to combine them. The search results were
showed in Fig. 1.
Selection criteria
Trials were eligible for inclusion if they met the follow-
ing criteria: 1) Randomized controlled trials or retro-
spective control trials; 2) The study compared the
efficacy and safety of combined application versus top-
ical or intravenous application of tranexamic acid in
primary THA; 3) The study evaluated at least one of
the outcome measures of total blood loss, postoperative
hemoglobin decline, transfusion rates, deep vein throm-
bosis (DVT) incidence, and pulmonary embolism (PE)
incidence. Studies were excluded if: 1) Patients received
other hemostasis treatment; 2) Patients had history of
thrombotic events (PE or DVT).
Data extraction
The included studies were examined by two investiga-
tors and key data were extracted including first author’s
name, the published year, study type, sample size, mean
age, anesthesia methods, TXA intervention, prosthesis
type, prophylactic antithrombotic therapy, transfusion
trigger, and surgical outcomes for the meta-analysis (in-
cluding total blood loss, postoperative hemoglobin de-
cline, transfusion rates, and postoperative complications:
VT, PE). When disagreement existed, it was resolved by
consulting another investigator.
Quality assessment
The quality of the randomized controlled trials was assessed
according to the Cochrane risk assessment scale and in-
cluded details of the methods of random sequence gener-
ation, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting, and other sources of bias.
The Methodological Index for Non-Randomized Studies
(MINORS) was used to assess non-RCTs. The assessments
were performed by two investigators independently. Any
disagreement was resolved by a third reviewer.
Statistical analysis
This meta-analysis was performed using RevMan 5.3.
The heterogeneity level among included studies was
assessed by using the value of P and I2. If I2 < 50%, P > 0.1,
this represented low heterogeneity between studies, and
a fixed-effect model was used, otherwise, a random-effect
model was used. For continuous outcomes, we calculated
the mean difference (MD) with 95% confidence interval
(CI). The risk difference (RD) with 95% CI was calculated
for dichotomous data. If necessary, sensitivity analysis




The search of electronic database identified 498 potentially
relevant references for preliminary review. After the scan of
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titles and abstracts, 489 studies were excluded. After the full
texts were assessed for eligibility, six RCTs and a retrospect-
ive study published between 2014 and 2016 were selected
for inclusion [20–26]. The characteristics of the included
studies are shown in Table 1.
The selected studies reported comparable baseline char-
acteristics of treatment groups regarding age, gender, Body
Mass Index (BMI), and preoperative laboratory parame-
ters (red blood cell specific volume: Hct and hemoglobin:
Hb). Six studies reported the transfusion trigger: less than
70 g/L for five studies and 80 g/L for the remaining study.
For thromboprophylaxis, two studies used low molecular
weight heparin (LMWH) combined with physical therapy,
one used enoxaparin combined with physical therapy, one
used enoxaparin and rivaroxaban, and one used rivaroxa-
ban combined with physical therapy. Two studies did not
report the use of thromboprophylaxis.
Risk of bias assessment
All included RCTs showed clear inclusion and exclusion
criteria. In four [20, 22–24] of the included RCTs, the
randomization algorithm was generated from a blinded
biostatistician or a computer. In one RCT [26], the alloca-
tion concealment was performed using opaque sealed
envelopes. One RCT [24] provided details of the double
blinding for treatments and the blinding of outcome
assessment. All RCTs reported complete outcome data. The
results of the quality of the included RCTs are shown in
Fig. 2. The MINORS scale was used to assess the retrospect-
ive study, as presented in Fig. 3.
Outcomes measures
Total blood loss (ml)
1) Comparisons between the combined group and the
topical group.
Six studies (1111patients) [20–23, 25, 26]
investigated total blood loss. Heterogeneity was
significant in the studies (P <0.00001; I2 = 95%),
so the random-effects model was used. The pooled
result revealed that combined application of TXA
significantly reduced total blood loss compared to
topical application of TXA. (MD = −162, 95% CI:
−265 to −60, P = 0.002. Figure 4a).
2) Comparisons between the combined group and the
intravenous group.
Seven studies (for a total of 1317 patients) [20–26]
compared total blood loss. Heterogeneity was
Fig. 1 The flow chart of studies selecting
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significant in the studies (P =0.0001; I2 = 78%), so the
random-effects model was used. The pooled result
revealed that the combined group exhibited lower
total blood loss than the intravenous group (MD=
−153, 95% CI: −201 to −105, P <0.00001. Figure 4b).
Postoperative hemoglobin decline (g/dl)
1) Comparison between the combined group and the
topical group.
Four reports (including 1003 patients) [21, 22, 25, 26]
reported the outcome of postoperative hemoglobin
decline. Significant heterogeneity was detected in the
studies (P =0.007; I2 = 75%), so the random-effects
model was used. The pooled results showed that the
combined application group showed postoperative
hemoglobin decline (MD= −1.06, 95% CI: −1.30 to
−0.82, P < 0.00001; Fig. 5a).
2) Comparison between the combined group and the
intravenous group.
Five studies (including 1209 patients) [21, 22, 24–26]
reported the outcome of postoperative hemoglobin
decline. Heterogeneity was significant in the studies
(P =0.01; I2 = 69%); so, the random-effects model
was used. The pooled results showed that the
combined application group exhibited lower
postoperative hemoglobin decline (MD = −0.56,
95% CI: −0.78 to −0.34, P < 0.00001; Fig. 5b).
Transfusion rates
1) Comparison between the combined group and the
topical group.
Table 1 The characteristics of included studies
Study
(year)












T:3 g; I: 1.5 g;
C:1 g (IV) + 2 g (T)
Cementless Enoxaparin + Physical therapy Hb <7 g/dL
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– T:0.1 g; I: l g;
C:1 g(IV) + 0.1 g(T)
Cemented Enoxaparin + rivaroxaban Hb <7 g/dL







T:1 g; I:1 g;
C:1 g(IV) + 1 g(T)
Cementless Rivaroxaban + Physical therapy Hb < 8 g/dL






T: 2 g; I: 30 mg/kg TXA;
C:30 mg/kg (IV) + 2 g (T)
Cementless – Hb <7 g/dL




– T: 2 g; I: 15 mg/kg TXA;
C:15 mg/kg (IV) + 2 g (T)
Cementless – –




– I:15 mg/kg TXA;
C:15 mg/kg (IV) + 1 g (T)
– Low-molecular-weight
heparin + Physical therapy
Hb <7 g/dL
C combined group, T topical group, I intravenous group, IV intravenous injection, Hb hemoglobin
Fig. 2 The quality of the randomized controlled trials
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Five studies (including 1071 patients) [20–22, 25, 26]
compared transfusion rates. No significant
heterogeneity was detected in the studies (P =0.97; I2
= 0%). Therefore, the fixed-effects model was used for
analysis. The results showed the combined application
group had lower transfusion rates (RD = −0.05, 95%
CI: −0.08 to −0.02, P = 0.0005; Fig. 6a).
2) Comparison between the combined group and the
intravenous group.
Six studies (including 1277 patients)
[20–22, 24–26] compared transfusion rates.
No significant heterogeneity was detected in
the studies (P =0.39; I2 = 5%). Therefore, the
fixed- effects model was used for analysis.
The results showed that the combined application
group had lower transfusion rates (RD = −0.04,
95% CI: −0.07 to −0.02, P = 0.0002; Fig. 6b).
Deep vein thrombosis (DVT)
1) Comparison between the combined group and the
topical group.
Six articles (for a total of 1111 patients)
[20–23, 25, 26] reported the incidence of DVT.
Fig. 3 Quality assessment for the non-randomized trial
Fig. 4 a: The comparison between the combined group and the topical group in total blood loss. b: The comparison between the combined
group and the intravenous group in total blood loss
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Fig. 5 a: The comparison between the combined group and the topical group in postoperative hemoglobin decline. b: The comparison
between the combined group and the intravenous group in postoperative hemoglobin decline
Fig. 6 a: The comparison between the combined group and the topical group in transfusion rates. b: The comparison between the combined
group and the intravenous group in transfusion rates
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No significant heterogeneity was found (P = 0.87;
I2 = 0%), so the fixed-effects model was used. It
showed no significant difference between the
groups (RD = 0.00, 95% CI: −0.01 to 0.02,
P = 0.93; Fig. 7a).
2) Comparison between the combined group and the
intravenous group.
Seven articles (for a total of 1317 patients) [20–26]
reported the incidence of DVT. No significant
heterogeneity was found (P =1; I2 = 0%), so the
fixed-effects model was used. It showed no
significant difference between the groups
(RD = 0.00, 95% CI: −0.01 to 0.01, P = 0.89; Fig. 7b).
Pulmonary embolism (PE)
1) Comparison between the combined group and the
topical group.
PE was reported in four included studies
(1003 patients) [21, 22, 25, 26]. No significant
heterogeneity was found (P = 1; I2 = 0%), therefore,
the fixed-effects model was used. It manifested no
significant difference between the treatments
(RD = 0.00, 95% CI: −0.01 to 0.01, P = 1; Fig. 8a).
2) Comparison between the combined group and the
intravenous group.
PE was reported in five included studies (1209
patients) [21, 22, 24–26]. No significant
heterogeneity was found (P = 1; I2 = 0%), therefore,
the fixed-effects model was used. It manifested no
significant difference between the groups (RD = 0.00,
95% CI: −0.01 to 0.01, P = 1; Fig. 8b).
Discussion
To our knowledge, this is the first meta-analysis comparing
the hemostatic efficacy and safety of the combined applica-
tion of intravenous and topical application of tranexamic
acid in primary THA. The most important finding of our
meta-analysis was that the combined application of TXA
was correlated with a significant lower total blood loss and
transfusion requirements without increasing rate of throm-
botic events (DVT or PE).
TXA has been shown to decrease blood loss and reduce
transfusion requirements, and has been successfully used in
surgical procedures including THA [8, 10–12]. Intravenous
or topical TXA use alone has been demonstrated to be
effective and safe in total hip arthroplasty [8, 13–16]. When
TXA is given intravenously, it is widely distributed through-
out the extracellular and intracellular compartment, and
rapidly reaches a maximum plasma concentration (in 5 to
15 min) [26, 27]. Local fibrinolysis can be inhibited from
the start of surgery [26]. Topical application of TXA may
Fig. 7 a: The comparison between the combined group and the topical group in the incidence rate of DVT. b: The comparison between the
combined group and the intravenous group in the incidence rate of DVT
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maintain a maximum local level for hemostasis by main-
taining fibrin clotting [26, 28]. The combined application of
TXA has been used in total knee arthroplasty with satisfac-
tory results [17–19]. To our knowledge, no meta-analysis
has evaluated the efficacy and safety of combined applica-
tion versus topical or intravenous administration of TXA in
THA. The primary endpoints of our study included total
blood loss, postoperative hemoglobin decline, and transfu-
sion rates. Our results revealed that the combined group
had lower total blood loss. Xie et al. [26] reported that com-
pared to IV TXA or topical TXA, combined administration
of TXA can additionally reduce total blood loss by 12 and
14%, respectively Zeng et al. [24] also reported that the
combined group had significantly lower total blood loss
than the intravenous group. The research results of Zhang
et al. [20] and Zhao et al. [25] are consistent with our
findings. Yue et al. [21] also favored a combined approach
by retrospective study.
The result of our meta-analysis evaluating transfusion
rates favored the combined group. Zhang et al. [20] re-
ported that there was no statistically significant difference
in transfusion rates for IV, topical, or combined adminis-
tration of TXA. All the results of the remaining studies
were consistent with the findings of our meta-analysis that
the combined group had a lower transfusion rate.
Thrombotic complications could induce severe results
and even death after THA, so it is urgent to determine
whether combined application of TXA increases the rate of
thrombotic events (DVT and PE). Many studies reported
that topical or intravenous administration of TXA was not
associated with an increased rate of thrombotic events [29–
32]. In our meta-analysis, all the included studies reported
no significant difference in the incidence rate of DVT or PE
in the combined, topical, or intravenous treatment groups.
This finding was in accordance with the results of our meta-
analysis. Sensitivity analysis based on the study type also
showed no statistical difference. Although the methods of
thromboprophylaxis differed in the included studies, our
study did not show any significant heterogeneity in DVT
and PE among these studies. However, due to the small
sample size and short follow-up in most of the included
studies, larger studies with more patients and longer follow-
up are required to confirm whether the combined treatment
strategy is safe without increasing thrombotic events.
Significant heterogeneity was detected in some outcomes
in our meta-analysis. The sensitivity analysis based on study
type demonstrated no statistically significant difference in
the outcomes. In four of the included RCTs, a blinded
biostatistician or a computer generated the randomization
algorithm. In one RCT,the allocation concealment was per-
formed using opaque sealed envelopes. One RCT included
details of the double blinding and the blinding of the out-
come assessment.
There are several limits of this meta-analysis. We included
a retrospective study in our analysis due to the limited
amount of published RCTs. This inclusion decreased the evi-
dence level of the meta-analysis to some extent. Although we
searched electronic databases systematically, some relevant
Fig. 8 a: The comparison between the combined group and the topical group in the incidence rate of PE. b: The comparison between the
combined group and the intravenous group in the incidence rate of PE
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studies might have been missed due to publication bias. Add-
itionally, the sample size was very small in most of the in-
cluded studies.
In addition, there was clinical heterogeneity in the re-
ports as follows: 1) Differences in surgical time, tech-
nique, approaches, and postoperative measures. 2)
Different anesthesia methods, which can affect blood
loss and transfusion requirements (general anesthesia
was related with an increased rate of adverse events and
blood transfusions compared with spinal anesthesia) [33,
34]. However, a larger sample size of patients and multi-
center studies are required to confirm this conclusion. 3)
Differences in the TXA dose, especially Zhang 2015 [20],
there was insufficient data to perform subgroup analysis
and the optimal dose still remains controversial. In order
to clarify the contributions of all these identified issues,
additional studies with larger sample sizes are needed.
The limitations of this study were as follows: 1) The
relatively small sample size of each primary study, espe-
cially Zhu 2016 [23]; and there was significant heterogen-
eity in total blood loss and postoperative hemoglobin
decline. However, we could not conduct subgroup analysis
due to insufficient data.2)In some RCTs, the methods of
random sequence generation, allocation concealment,
blinding, and selective outcome reporting were unclear or
not described, which may influence the stability of our
outcomes to some extent. 3)A retrospective study was in-
cluded due to the limitation of studies, which also lowered
the robust analysis. 4) Differences in surgical time, tech-
nique, approaches, and postoperative measures may have
influenced the results. 5) There is publication bias.
Conclusion
The group that received the combined treatment had lower
total blood loss, postoperative hemoglobin decline, and
transfusion rates without an increased rate of thrombotic
events (DVT or PE). The topical or intravenous use of
TXA in primary THA is generally considered to be safe
and effective. This meta-analysis demonstrated that com-
bined TXA application may be superior to topical or intra-
venous application of TXA alone. However, larger, high-
quality randomized control trials are required for greater
confidence in this finding.
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